Atopic dermatitis (eczema) trials in Japan

In Japan 11 Also abroad 251

11 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
Where
Fukuoka
Age
18 years to 55 years
People
63
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07604324
Phase 3Taking people
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Where
Chuo-ku, Habikino, Kagoshima, Nagoya, Okayama, Saitama, Sakai, Shimotsuga-gun, Tachikawa, Toshima-ku, Yahaba-cho, Yokohama
Age
12 years and over
People
1,375 worldwide
Run by
Pfizer
See details and how to joinNCT07783425 · EU 2026-525743-32-00
Phase 3Taking people
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Where
Fukuoka, Sakai, Setagaya-ku, Yokohama
Age
2 years to 11 years
People
450 worldwide
Run by
Pfizer
See details and how to joinNCT06807281 · EU 2023-509124-18-00
Phase 2Taking people
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Where
Chuo-ku, Kawasaki-shi, Sakai, Takasaki, Yokohama
Age
18 years to 64 years
People
165 worldwide
Run by
Pfizer
See details and how to joinNCT07216027 · EU 2025-522965-31-00
No phaseTaking people
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Where
Habikino-shi, Hamamatsu, Marugame-shi
Age
12 years and over
People
1,000 worldwide
Run by
Sanofi
See details and how to joinNCT07290803
Phase 3Enrolling by invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Asahikawa, Fukuyama, Habikino, Hiroshima, Ina, Kumagaya, Kyoto, Okayama, Sagamihara, Sakai, Toshima City, Toyoake
Age
6 months to 18 years
People
338 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05735483 · EU 2022-501478-21-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
Where
Matsudo, Nagaoka, Osaka, Sakai, Shinagawa, Teine-ku
Age
12 years and over
People
375 worldwide
Run by
Pfizer
See details and how to joinNCT07765888 · EU 2026-526155-65-00
Phase 2Taking people
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Where
Fukuoka, Habikino, Kawasaki, Kyoto, Matsudo, Nagoya, Shinagawa Ku, Yokohama
Age
18 years to 100 years
People
224 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06947993 · EU 2024-519081-49-00
Phase 3Taking people
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Where
Fukuoka, Sakai, Setagaya-ku, Yokohama
Age
6 years to 11 years
People
150 worldwide
Run by
Pfizer
See details and how to joinNCT06807268 · EU 2023-509121-51-00
Phase 3Not yet taking people in Japan
A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis
Where
Tokyo
Age
3 months to 14 years
People
198
Run by
Otsuka Pharmaceutical Co., Ltd.
See details and how to joinNCT07184645
Phase 3Not yet taking people in Japan
A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
Where
Tokyo
Age
15 years to 70 years
People
156
Run by
Otsuka Pharmaceutical Co., Ltd.
See details and how to joinNCT07173478